RYZ-801 Actinium-225 HCC Phase I — PatSnap Eureka
RYZ-801 Actinium-225 Phase I in HCC: Tracking BMS/RayzeBio's Alpha Radiopharma Program
RYZ-801 is BMS/RayzeBio's investigational ²²⁵Ac-labeled peptide radioconjugate in Phase I evaluation for hepatocellular carcinoma — a high-unmet-need indication with limited systemic options. Monitor emerging patent filings, congress disclosures, and pipeline intelligence with PatSnap Eureka.
HCC and the Rise of Actinium-225 Targeted Alpha Therapy
Hepatocellular carcinoma (HCC) represents a major unmet medical need, accounting for the majority of primary liver cancers globally and characterized by limited systemic treatment options in advanced stages. The disease burden is substantial, and the therapeutic landscape remains constrained for patients progressing beyond first-line agents.
Actinium-225 (²²⁵Ac)-labeled targeted alpha therapy (TAT) has emerged as a high-interest modality in radioligand therapy (RLT), leveraging the short-range, high-linear-energy-transfer (LET) properties of alpha particles to deliver cytotoxic radiation with precision. Unlike beta-emitting radioligands, alpha particles deposit energy over a very short tissue range — typically a few cell diameters — reducing off-target irradiation while maximizing tumor cell kill.
RYZ-801 is BMS/RayzeBio's investigational ²²⁵Ac-labeled peptide radioconjugate currently in Phase I evaluation for HCC. It represents part of the broader alpha radiopharma expansion program following Bristol Myers Squibb's acquisition of RayzeBio, a move that signaled major pharma's commitment to actinium-based radioligand platforms. The ClinicalTrials.gov registry and congress abstract databases remain the primary sources for first-in-human data readouts at this stage of development.
Alpha Radioligand Therapy: Modality Characteristics & Data Gap Assessment
Understanding the physical properties of ²²⁵Ac TAT and the intelligence coverage landscape for RYZ-801 at its current development stage.
Alpha vs Beta Radioligand Therapy: Key Physical Properties
Actinium-225 TAT leverages short-range, high-LET alpha particles — a mechanistically distinct approach from beta-emitter RLT platforms.
RYZ-801 Data Source Coverage: Intelligence Gap Map
Pre-publication Phase I assets typically appear in congress abstracts before patent or academic databases — creating a structured intelligence gap that monitoring tools can bridge.
Why RYZ-801 Phase I Data Is Absent from Standard Databases
Three structural reasons explain why first-in-human Phase I results for RYZ-801 are not yet retrievable from patent and academic literature repositories.
Recency of Data Disclosure
RYZ-801 Phase I data in HCC may be too recently disclosed — for example via conference abstract, press release, or preprint — to be indexed in the patent and academic literature databases queried at the time of analysis.
Conference-first disclosure timelineProprietary Data Stage
First-in-human Phase I results are frequently presented at oncology congresses such as ASCO, ESMO, and AACR prior to peer-reviewed publication or patent filing, placing them outside standard searchable literature repositories at the time of query.
Pre-publication congress presentationDatabase Coverage Gap
The specific compound name "RYZ-801" or its INN/code equivalent may not yet appear in indexed patent filings or academic manuscripts. Compound codes for investigational radioconjugates often lag behind clinical disclosure by months.
Compound code indexing lagRe-Execute Searches in 30–60 Days
As indexing of recent publications catches up to conference disclosure timelines, database searches should be re-executed within 30–60 days. PatSnap's patent analytics platform enables automated monitoring so analysts are alerted the moment new records appear.
30–60 day re-query windowRecommended Intelligence Pathways for RYZ-801 Monitoring
Structured next steps for analysts tracking BMS/RayzeBio's alpha radiopharma expansion program and RYZ-801 Phase I data readouts.
Query ClinicalTrials.gov Directly
Query ClinicalTrials.gov directly for NCT identifiers associated with RYZ-801 or RayzeBio HCC programs. NCT registration typically precedes first-patient-in and provides protocol details, endpoints, and site information before any patent or literature disclosure.
Search Congress Abstract Databases
Search congress abstract databases at ASCO, ESMO, and SNMMI for RYZ-801 or ²²⁵Ac-HCC presentations from 2023–2025. Phase I safety and preliminary efficacy data for radioligand assets are routinely first disclosed at nuclear medicine and oncology congresses.
RYZ-801 Intelligence Source Tracker: Status by Repository
| Intelligence Source | Coverage Type | RYZ-801 Status | Recommended Action |
|---|---|---|---|
| Patent Databases | IP filings, radioconjugate claims | No Results | Re-query in 30–60 days |
| Academic Literature | Peer-reviewed publications, preprints | No Results | Re-query in 30–60 days |
| ClinicalTrials.gov | NCT registration, protocol details | Query Now | Search RYZ-801 / RayzeBio HCC |
| ASCO Abstracts | Phase I safety, preliminary efficacy | Monitor | Search 2023–2025 abstracts |
| ESMO Abstracts | Phase I safety, preliminary efficacy | Monitor | Search 2023–2025 abstracts |
| SNMMI Abstracts | Nuclear medicine / TAT disclosures | Monitor | Search ²²⁵Ac-HCC presentations |
| BMS Investor Relations | Pipeline updates, IND filings, milestones | Monitor | Monitor pipeline disclosures |
Monitor All Sources Simultaneously with PatSnap Eureka
PatSnap Eureka aggregates patent, literature, and pipeline intelligence in one AI-native platform — built for life sciences R&D and IP teams.
RYZ-801 Actinium-225 HCC — key questions answered
RYZ-801 is BMS/RayzeBio's investigational actinium-225 (²²⁵Ac)-labeled peptide radioconjugate currently in Phase I evaluation for hepatocellular carcinoma (HCC). It is part of BMS and RayzeBio's broader alpha radiopharma expansion program leveraging targeted alpha therapy (TAT).
Actinium-225 (²²⁵Ac)-labeled targeted alpha therapy (TAT) has emerged as a high-interest modality in radioligand therapy (RLT), leveraging the short-range, high-linear-energy-transfer (LET) properties of alpha particles to deliver cytotoxic radiation with precision to tumor cells.
First-in-human Phase I results are frequently presented at oncology congresses (e.g., ASCO, ESMO, AACR) prior to peer-reviewed publication or patent filing, placing them outside standard searchable literature repositories at the time of query. The specific compound name RYZ-801 or its INN/code equivalent may not yet appear in indexed patent filings or academic manuscripts.
Hepatocellular carcinoma (HCC) represents a major unmet medical need, accounting for the majority of primary liver cancers globally and characterized by limited systemic treatment options in advanced stages.
Analysts should query ClinicalTrials.gov directly for NCT identifiers associated with RYZ-801 or RayzeBio HCC programs, search congress abstract databases (ASCO, ESMO, SNMMI) for RYZ-801 or ²²⁵Ac-HCC presentations from 2023–2025, and monitor BMS investor relations and RayzeBio pipeline disclosures for IND filings and Phase I data readouts.
Targeted alpha therapy (TAT) uses alpha particles which have short-range, high-linear-energy-transfer (LET) properties, enabling cytotoxic radiation to be delivered with precision. This distinguishes TAT from beta-emitter-based radioligand therapy (RLT) in terms of the physical range and energy deposition characteristics of the emitted particles.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About RYZ-801Stay Ahead of Alpha Radiopharma Pipeline Developments
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D.
References
- ClinicalTrials.gov — NCT Registry for RYZ-801 / RayzeBio HCC Programs — U.S. National Library of Medicine clinical trial registration database. Recommended primary source for RYZ-801 protocol details and NCT identifiers.
- American Society of Clinical Oncology (ASCO) — Abstract Database — Annual congress abstract database. Recommended source for RYZ-801 and ²²⁵Ac-HCC presentations from 2023–2025.
- World Health Organization (WHO) — Global Cancer Observatory: Liver Cancer — WHO global cancer statistics and HCC epidemiology data. Referenced for HCC disease burden context.
- Society of Nuclear Medicine and Molecular Imaging (SNMMI) — Annual Meeting Abstracts — Nuclear medicine congress abstracts including targeted alpha therapy and radioligand therapy disclosures.
- European Society for Medical Oncology (ESMO) — Congress Abstract Database — ESMO annual meeting and specialty congress abstracts. Recommended monitoring source for RYZ-801 Phase I disclosures.
- PatSnap Life Sciences Intelligence Platform — AI-native patent and literature intelligence platform used for RYZ-801 database search execution and pipeline monitoring framework.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Note: No peer-reviewed publications or patent filings specific to RYZ-801 were retrievable at the time of analysis. This page documents the intelligence gap and recommended monitoring pathways consistent with PatSnap Eureka's analytical framework.
PatSnap Eureka searches patents and research to answer instantly.